| pubmed-article:17099725 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17099725 | lifeskim:mentions | umls-concept:C0292198 | lld:lifeskim |
| pubmed-article:17099725 | lifeskim:mentions | umls-concept:C0598766 | lld:lifeskim |
| pubmed-article:17099725 | lifeskim:mentions | umls-concept:C1332738 | lld:lifeskim |
| pubmed-article:17099725 | lifeskim:mentions | umls-concept:C1519692 | lld:lifeskim |
| pubmed-article:17099725 | pubmed:issue | 20 | lld:pubmed |
| pubmed-article:17099725 | pubmed:dateCreated | 2007-5-3 | lld:pubmed |
| pubmed-article:17099725 | pubmed:abstractText | p18(Ink4c) functions as a dedicated inhibitor of cyclin-D-dependent kinases. Loss of Ink4c predisposes mice to tumor development and, in a dose-dependent manner, complements the tumor-promoting effects of various oncogenes. We have now addressed whether Ink4c loss impacts B-cell tumor development in the Emu-Myc transgenic mouse, a model of human Burkitt lymphoma. Loss of one or both alleles did not influence the onset of lymphoma in Emu-Myc transgenics, and did not appreciably affect Myc's proliferative or apoptotic responses in precancerous B cells. Nevertheless, Ink4c loss modulated the effects of Myc-induced transformation by decreasing the frequency of Arf loss, an ordinarily common event in Emu-Myc-induced lymphomas. | lld:pubmed |
| pubmed-article:17099725 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17099725 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17099725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17099725 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17099725 | pubmed:month | May | lld:pubmed |
| pubmed-article:17099725 | pubmed:issn | 0950-9232 | lld:pubmed |
| pubmed-article:17099725 | pubmed:author | pubmed-author:YangCC | lld:pubmed |
| pubmed-article:17099725 | pubmed:author | pubmed-author:ClevelandJ... | lld:pubmed |
| pubmed-article:17099725 | pubmed:author | pubmed-author:RousselM FMF | lld:pubmed |
| pubmed-article:17099725 | pubmed:author | pubmed-author:NilssonJ AJA | lld:pubmed |
| pubmed-article:17099725 | pubmed:author | pubmed-author:NilssonL MLM | lld:pubmed |
| pubmed-article:17099725 | pubmed:author | pubmed-author:KellerU BUB | lld:pubmed |
| pubmed-article:17099725 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17099725 | pubmed:day | 3 | lld:pubmed |
| pubmed-article:17099725 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:17099725 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17099725 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17099725 | pubmed:pagination | 2833-9 | lld:pubmed |
| pubmed-article:17099725 | pubmed:dateRevised | 2007-12-3 | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:meshHeading | pubmed-meshheading:17099725... | lld:pubmed |
| pubmed-article:17099725 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17099725 | pubmed:articleTitle | Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis. | lld:pubmed |
| pubmed-article:17099725 | pubmed:affiliation | Department of Biochemistry, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. | lld:pubmed |
| pubmed-article:17099725 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17099725 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17099725 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:12578 | entrezgene:pubmed | pubmed-article:17099725 | lld:entrezgene |
| entrez-gene:12580 | entrezgene:pubmed | pubmed-article:17099725 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17099725 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17099725 | lld:entrezgene |
